RNAC

Business Context and Reporting Period

Company: Cartesian Therapeutics, Inc. (formerly Selecta Biosciences, Inc.)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2025
Business Overview: A clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases. The company's lead product candidate, Descartes-08, is in Phase 3 development for myasthenia gravis (MG). The company operates as a single segment and is classified as a smaller reporting company.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Total revenue for the six months ended June 30, 2025, dropped to $1.4 million from $39.3 million in the prior year period. This decrease is primarily due to the absence of a $30.0 million development milestone recognized in 2024 under the Sobi License and the termination of the Astellas Agreement.
• Net Loss Improvement: The company reported a net loss of $1.8 million for the six months ended June 30, 2025, a significant improvement from the $43.0 million net loss in the same period in 2024. This improvement was driven by non-cash gains from the change in fair value of the Contingent Value Right (CVR) liability ($35.6 million gain) and warrant liabilities ($2.5 million gain).
• Operating Expenses: Research and development expenses increased by 32% year-over-year to $29.5 million, driven by the ongoing Phase 3 AURORA trial for Descartes-08 and increased headcount. General and administrative expenses decreased by 6% to $15.6 million, largely due to reduced professional fees related to the 2023 Merger.
• Cash Position: Cash, cash equivalents, and restricted cash decreased by $52.2 million during the six-month period, primarily due to operating cash outflows of $40.6 million and CVR distribution payments of $7.8 million.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management believes existing cash resources ($162.1 million) will fund operations into mid-2027. The company expects to continue incurring operating losses for the foreseeable future.
• Contingent Value Rights (CVR): A significant liability of $352.1 million remains on the balance sheet. This liability is settled solely through cash flows from the Sobi License and legacy asset monetization. 100% of milestone payments and royalties from the Sobi License are distributed to CVR holders net of deductions.
• Key Risks:
  • Dependence on third-party collaborators (e.g., Sobi) for funding and commercialization of legacy assets.
  • Uncertainty regarding clinical trial outcomes and regulatory approvals for Descartes-08.
  • Potential need for additional capital, which could be dilutive.
  • Volatility in the fair value of CVR and warrant liabilities impacting reported earnings.
• Unusual Items: The net income for the three months ended June 30, 2025 ($15.9 million) was largely non-operational, driven by a $35.3 million gain from the revaluation of the CVR liability.

Investor Verification Checklist

• Cash Runway: Verify the accuracy of the "mid-2027" funding estimate against current burn rates and potential acceleration of clinical costs.
• CVR Liability Dynamics: Review the Monte Carlo assumptions used to value the $352.1 million CVR liability, as changes in these assumptions significantly impact net income/loss without affecting cash flow.
• Sobi License Milestones: Monitor the status of the SEL-212 program and potential future milestone payments, noting that proceeds are directed to CVR holders, not the company's general operations.
• Phase 3 Trial Progress: Confirm enrollment and data readout timelines for the Descartes-08 AURORA trial, which is the primary driver of current R&D spend.
• Stock-Based Compensation: Assess the impact of the $5.8 million stock-based compensation expense (six months 2025) on future cash burn and dilution.